Global Top Players in Intraocular Lens (IOL) Market

Ophthalmology

How will Pharmacotherapies help the growing num...

Presbyopia is the gradual loss of near-focusing ability that occurs with age—a condition that occurs when people get older and prevails as a quite common one in many individuals. The reasons for th...

Jun 21, 2021

age-related-hearing-loss-device-market-analysis
Age-related Hearing Loss Device Market Dynamics Expected to Step into Growth Quadrant

Age-related hearing loss (ARHL), also known as presbycusis, is a complicated disease that has been observed in tens of millions of people around the world. It is defined as a progressive, irreversible, and symmetrical bilateral neurosensory hearing loss caused by cochlea degeneration, in which sound-induced vibrati...

Find More
eye-disorders-treatment-market-Errors-Refractive-Age-Related-Macular-Degeneration-Cataract-Glaucoma-Diabetic-Retinopathy-Novartis-Roche-Eyenovia-Allergan
How Pharmaceutical Companies Are Mitigating The Gap In The Eye Disorders Treatment Market

The eyes are one of the most precious and delicate parts of the human body. Around 80% of the information from the surrounding environment that the human perceives comes from our eyes. The eyes require the best protection and care, as a slight disability can severely impact day-to-day activities and can also have l...

Find More
recent-pharma-news-update
MedTech Industry Roars Back as FDA Approvals Soar

Zimmer Biomet Receives FDA Approval for its Rosa System On 20 April 2021, Zimmer Biomet received FDA 510(k) clearance for its Rosa Partial Knee system for robotically-assisted partial knee replacement surgeries. This is the new edition to Zimmer Biomet's Rosa Robotics platform, which comprises the Rosa Knee syst...

Find More

More Views & Analysis

recent-pharma-happenings-for-bluebird-pfizer-guardant-astrazeneca
Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the ...

Find More

Hepatitis D Market | Hepatitis D Treatment Market | HDV Market
Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook?

Recent years have been experiencing a dramatic increase in the number of Hepatitis D cases. It is spreading at a rapid rate. DelveInsight estimated that the total diagnosed Hepatitis D prevalence was reported to be 204,976 in 2017 in the 7MM (the US, EU5 (the UK, Germany, Spain, France, and Italy) and Japan). Furth...

Find More

8-Most-Common-Foods-Allergies-and-their-signs-symptoms-causes-risk-factors-treatment-options-epidemiology
8 Of The Most Common Foods Allergies – Do You Have One?

As per the  Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful.  Upon exposure to the food allergen, the IgE antibodi...

Find More

recent-pharma-biotech-news-and-updates-for-zimmer-bayer-ovid-merck-janssen-roche
Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Roche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. The company anticipates the tes...

Find More

Retinal Vein Occlusion Market | Retinal Vein Occlusion Market Emerging Therapies | Retinal Vein Occlusion Market Pharma companies
Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market. T...

Find More

Retinal vein occlusion drug market
What are the options available for the treatment of Retinal vein occlusion?

Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a significant amount of other ocular complications. Any kind of blockage in the vein of the eye that carries blood from the reti...

Find More

The medical device (MedTech) industry has small and big companies operating in various segments such.....

Find More

Medical device manufacturing and development is a high-capital demanding endeavor and therefore the .....

Find More

Market intelligence (MI) is described as the information or the data derived by a company from the m.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

It was assumed initially that Alzheimer’s Disease was a rare condition, but now it is considered t.....

Find More

In the present scenario, the 3-D printing and bioprinting technology in the medical devices industry.....

Find More